2oc2 › Citations

The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.

Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, Acharya KR
Biochemistry 46 5473-8 (2007)
Cited: 42 times
EuropePMC logo PMID: 17439247

Abstract

Angiotensin I-converting enzyme (ACE) is central to the regulation of the renin-angiotensin system and is a key therapeutic target for combating hypertension and related cardiovascular diseases. Currently available drugs bind both active sites of its two homologous domains, although it is now understood that these domains function differently in vivo. The recently solved crystal structures of both domains (N and C) open the door to new domain-specific inhibitor design, taking advantage of the differences between these two large active sites. Here we present the first crystal structure at a resolution of 2.25 A of testis ACE (identical to the C domain of somatic ACE) with the highly C-domain-specific phosphinic inhibitor, RXPA380. Testis ACE retains the same conformation as seen in previously determined inhibitor complexes, but the RXPA380 central backbone conformation is more similar to that seen for the inhibitor captopril than enalaprilat. The RXPA380 molecule occupies more subsites of the testis ACE active site than the previously determined inhibitors and possesses bulky moieties that extend into the S2' and S2 subsites. Thus the high affinity of RXPA380 for the testis ACE/somatic ACE C domain is explained by the interaction of these bulky moieties with residues unique to these domains, specifically Phe 391, Val 379, and Val 380, that are not found in the N domain. The characterization of the extended active site and the binding of a potent C-domain-selective inhibitor provide the first structural data for the design of truly domain-specific pharmacophores.

Reviews - 2oc2 mentioned but not cited (4)

  1. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC, Llorens-Cortes C, Ehlers MR, Sturrock ED. Pharmacol Rev 71 539-570 (2019)
  2. Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors. Caballero J. Molecules 25 E295 (2020)
  3. Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Zheng W, Tian E, Liu Z, Zhou C, Yang P, Tian K, Liao W, Li J, Ren C. Front Pharmacol 13 968104 (2022)
  4. Phosphinic Peptides as Tool Compounds for the Study of Pharmacologically Relevant Zn-Metalloproteases. Georgiadis D, Skoulikas N, Papakyriakou A, Stratikos E. ACS Pharmacol Transl Sci 5 1228-1253 (2022)

Articles - 2oc2 mentioned but not cited (10)

  1. Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. Guerrero L, Castillo J, Quiñones M, Garcia-Vallvé S, Arola L, Pujadas G, Muguerza B. PLoS One 7 e49493 (2012)
  2. Structural protein-ligand interaction fingerprints (SPLIF) for structure-based virtual screening: method and benchmark study. Da C, Kireev D. J Chem Inf Model 54 2555-2561 (2014)
  3. Separation and Characterization of Antioxidative and Angiotensin Converting Enzyme Inhibitory Peptide from Jellyfish Gonad Hydrolysate. Zhang Q, Song C, Zhao J, Shi X, Sun M, Liu J, Fu Y, Jin W, Zhu B. Molecules 23 E94 (2018)
  4. Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies. Wang X, Wu S, Xu D, Xie D, Guo H. J Chem Inf Model 51 1074-1082 (2011)
  5. Interkingdom pharmacology of Angiotensin-I converting enzyme inhibitor phosphonates produced by actinomycetes. Kramer GJ, Mohd A, Schwager SL, Masuyer G, Acharya KR, Sturrock ED, Bachmann BO. ACS Med Chem Lett 5 346-351 (2014)
  6. Prediction of COVID-19 manipulation by selective ACE inhibitory compounds of Potentilla reptant root: In silico study and ADMET profile. Xu Y, Al-Mualm M, Terefe EM, Shamsutdinova MI, Opulencia MJC, Alsaikhan F, Turki Jalil A, Hammid AT, Enayati A, Mirzaei H, Khori V, Jabbari A, Salehi A, Soltani A, Mohamed A. Arab J Chem 15 103942 (2022)
  7. Impaired proteostasis contributes to renal tubular dysgenesis. de Oliveira RM, Marijanovic Z, Carvalho F, Miltényi GM, Matos JE, Tenreiro S, Oliveira S, Enguita FJ, Stone R, Outeiro TF. PLoS One 6 e20854 (2011)
  8. Gaussian Accelerated Molecular Dynamics Simulations Investigation on the Mechanism of Angiotensin-Converting Enzyme (ACE) C-Domain Inhibition by Dipeptides. Li C, Liu K, Chen S, Han L, Han W. Foods 11 327 (2022)
  9. Extrapolative prediction using physically-based QSAR. Cleves AE, Jain AN. J Comput Aided Mol Des 30 127-152 (2016)
  10. Toxicity of Three Optical Brighteners: Potential Pharmacological Targets and Effects on Caenorhabditis elegans. Castro-Sierra I, Duran-Izquierdo M, Sierra-Marquez L, Ahumedo-Monterrosa M, Olivero-Verbel J. Toxics 12 51 (2024)


Reviews citing this publication (3)

  1. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, Shen XZ, Fuchs S, Touyz RM. Pharmacol Rev 65 1-46 (2013)
  2. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. Guang C, Phillips RD, Jiang B, Milani F. Arch Cardiovasc Dis 105 373-385 (2012)
  3. How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor. Regulska K, Stanisz B, Regulski M, Murias M. Drug Discov Today 19 1731-1743 (2014)

Articles citing this publication (25)

  1. Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. Mucha A, Kafarski P, Berlicki Ł. J Med Chem 54 5955-5980 (2011)
  2. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Masuyer G, Schwager SL, Sturrock ED, Isaac RE, Acharya KR. Sci Rep 2 717 (2012)
  3. Studies on the molecular recognition between bioactive peptides and angiotensin-converting enzyme. Pina AS, Roque AC. J Mol Recognit 22 162-168 (2009)
  4. Synthesis, characterization and antioxidant activity of angiotensin converting enzyme inhibitors. Bhuyan BJ, Mugesh G. Org Biomol Chem 9 1356-1365 (2011)
  5. Ala-Val-Phe and Val-Phe: ACE inhibitory peptides derived from insect protein with antihypertensive activity in spontaneously hypertensive rats. Vercruysse L, Van Camp J, Morel N, Rougé P, Herregods G, Smagghe G. Peptides 31 482-488 (2010)
  6. Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide. Akif M, Schwager SL, Anthony CS, Czarny B, Beau F, Dive V, Sturrock ED, Acharya KR. Biochem J 436 53-59 (2011)
  7. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Watermeyer JM, Kröger WL, O'Neill HG, Sewell BT, Sturrock ED. Biochem J 428 67-74 (2010)
  8. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme. Masuyer G, Akif M, Czarny B, Beau F, Schwager SL, Sturrock ED, Isaac RE, Dive V, Acharya KR. FEBS J 281 943-956 (2014)
  9. Isolation, identification and molecular docking studies of a new isolated compound, from Onopordon acanthium: a novel angiotensin converting enzyme (ACE) inhibitor. Sharifi N, Souri E, Ziai SA, Amin G, Amini M, Amanlou M. J Ethnopharmacol 148 934-939 (2013)
  10. Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity. Cozier GE, Schwager SL, Sharma RK, Chibale K, Sturrock ED, Acharya KR. FEBS J 285 1477-1490 (2018)
  11. The molecular mechanisms of interactions between bioactive peptides and angiotensin-converting enzyme. Pan D, Guo H, Zhao B, Cao J. Bioorg Med Chem Lett 21 3898-3904 (2011)
  12. ACE for all - a molecular perspective. Harrison C, Acharya KR. J Cell Commun Signal 8 195-210 (2014)
  13. Interpretable correlation descriptors for quantitative structure-activity relationships. Spowage BM, Bruce CL, Hirst JD. J Cheminform 1 22 (2009)
  14. The toxicity of angiotensin converting enzyme inhibitors to larvae of the disease vectors Aedes aegypti and Anopheles gambiae. Abu Hasan Z', Williams H, Ismail NM, Othman H, Cozier GE, Acharya KR, Isaac RE. Sci Rep 7 45409 (2017)
  15. Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme. Sharma U, Cozier GE, Sturrock ED, Acharya KR. J Med Chem 63 5488-5500 (2020)
  16. Novel Angiotensin-I Converting Enzyme Inhibitory Peptides Isolated From Rice Wine Lees: Purification, Characterization, and Structure-Activity Relationship. He Z, Liu G, Qiao Z, Cao Y, Song M. Front Nutr 8 746113 (2021)
  17. Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. Denti P, Sharp SK, Kröger WL, Schwager SL, Mahajan A, Njoroge M, Gibhard L, Smit I, Chibale K, Wiesner L, Sturrock ED, Davies NH. Eur J Pharm Sci 56 113-119 (2014)
  18. Evidence for an angiotensin-converting enzyme (ACE) polymorphism in the crayfish Astacus leptodactylus. Kamech N, Simunic J, Franklin SJ, Francis S, Tabitsika M, Soyez D. Peptides 28 1368-1374 (2007)
  19. Design, Synthesis, and Study of a Novel RXPA380-Proline Hybrid (RXPA380-P) as an Antihypertensive Agent. Abdou MM, Dong D, O'Neill PM, Amigues E, Matziari M. ACS Omega 7 35035-35043 (2022)
  20. Unprecedented Convergent Synthesis of Sugar-Functionalization of Phosphinic Acids under Metal-Free Conditions. Abdou MM, O'Neill PM, Amigues E, Matziari M. ACS Omega 7 21444-21453 (2022)
  21. Crystal structure of a peptidyl-dipeptidase K-26-DCP from Actinomycete in complex with its natural inhibitor. Masuyer G, Cozier GE, Kramer GJ, Bachmann BO, Acharya KR. FEBS J 283 4357-4369 (2016)
  22. New Insights on Glutathione's Supramolecular Arrangement and Its In Silico Analysis as an Angiotensin-Converting Enzyme Inhibitor. Aguiar ASN, Borges ID, Borges LL, Dias LD, Camargo AJ, Perjesi P, Napolitano HB. Molecules 27 7958 (2022)
  23. QM/MM investigation of the catalytic mechanism of angiotensin-converting enzyme. Mu X, Zhang C, Xu D. J Mol Model 22 132 (2016)
  24. Structural basis for the inhibition of human angiotensin-1 converting enzyme by fosinoprilat. Cozier GE, Newby EC, Schwager SLU, Isaac RE, Sturrock ED, Acharya KR. FEBS J 289 6659-6671 (2022)
  25. Accurate aqueous proton dissociation constants calculations for selected angiotensin-converting enzyme inhibitors. Sramko M, Smiesko M, Remko M. J Biomol Struct Dyn 25 599-608 (2008)


Related citations provided by authors (1)

  1. The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.. Anthony CS, Corradi HR, Schwager SL, Redelinghuys P, Georgiadis D, Dive V, Acharya KR, Sturrock ED J Biol Chem 285 35685-93 (2010)

Quick links